| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Department of Neuroscience, Neurocrine Biosciences, Inc., San Diego, California 92121
Address all correspondence and requests for reprints to: Mary Ann Pelleymounter Neurocrine Biosciences, Inc., 10555 Science Center Drive, San Diego, California 92121. E-mail: MPelleymounter{at}neurocrine.com
Although there is considerable information regarding the role of brain CRF in energy balance, relatively little is known about the role of urocortin (UCN), which is an equally potent anorexic agent. Therefore, the effects of intracerebroventricular (icv) administration of UCN (0.01–1 nmol/day) on food intake and body weight were assessed over a period of 13 days and compared with data from CRF-infused counterparts. Although both peptides dose dependently reduced food intake and weight gain, the effects of CRF were much greater in magnitude than those of UCN, particularly on body weight. Pair-feeding studies suggested that, while the effects of CRF on body weight could not be completely explained by appetite suppression, the effects of UCN appeared to be due to its initial impact on food intake. CRF increased brown adipose fat pad and adrenal weights, whereas it reduced thymus and spleen weights. CRF also increased serum corticosterone, triglyceride, FFA, and cholesterol levels, whereas it reduced glucose. UCN did not produce any consistent changes in any of these indices of sympathetic nervous system activation. Concurrent administration of the CRF2-selective antagonist, antisauvagine-30 (ASV-30) (30 nmol/day) completely reversed or attenuated the effects of UCN and CRF (1 nmol/day) on food intake and body weight. ASV-30 did not significantly attenuate any of the above CRF-induced changes in tissue weights or serum chemistry. These data suggest that the central CRF2 receptor may primarily mediate the anorexic, but not the metabolic effects of CRF.
This article has been cited by other articles:
 |
|
 |
|
  G. Gourcerol, L. Wang, Y. H. Wang, M. Million, and Y. Tache Urocortins and Cholecystokinin-8 Act Synergistically to Increase Satiation in Lean But Not Obese Mice: Involvement of Corticotropin-Releasing Factor Receptor-2 Pathway Endocrinology, December 1, 2007; 148(12): 6115 - 6123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. P. Bakshi, S. M. Newman, S. Smith-Roe, K. A. Jochman, and N. H. Kalin Stimulation of Lateral Septum CRF2 Receptors Promotes Anorexia and Stress-Like Behaviors: Functional Homology to CRF1 Receptors in Basolateral Amygdala J. Neurosci., September 26, 2007; 27(39): 10568 - 10577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cottone, V. Sabino, T. R. Nagy, D. V. Coscina, and E. P. Zorrilla Feeding microstructure in diet-induced obesity susceptible versus resistant rats: central effects of urocortin 2 J. Physiol., September 1, 2007; 583(2): 487 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kobelt, M. Goebel, A. Stengel, M. Schmidtmann, I. R. van der Voort, J. J. Tebbe, R. W. Veh, B. F. Klapp, B. Wiedenmann, L. Wang, et al. Bombesin, but not amylin, blocks the orexigenic effect of peripheral ghrelin Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2006; 291(4): R903 - R913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Carlin, W. W. Vale, and T. L. Bale Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis PNAS, February 28, 2006; 103(9): 3462 - 3467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Seymour, S. L. Dettloff, J. E. Jones, and G. N. Wade Corticotropin-releasing factor receptor subtypes mediating nutritional suppression of estrous behavior in Syrian hamsters Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R418 - R423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. N. Wade and J. E. Jones Neuroendocrinology of nutritional infertility Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2004; 287(6): R1277 - R1296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schulz, K. Paulus, and H. Lehnert Central Nervous and Metabolic Effects of Intranasally Applied Leptin Endocrinology, June 1, 2004; 145(6): 2696 - 2701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Seres, S. R. Bornstein, P. Seres, H. S. Willenberg, K. M. Schulte, W. A. Scherbaum, and M. Ehrhart-Bornstein Corticotropin-Releasing Hormone System in Human Adipose Tissue J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 965 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Bale, K. R. Anderson, A. J. Roberts, K.-F. Lee, T. R. Nagy, and W. W. Vale Corticotropin-Releasing Factor Receptor-2-Deficient Mice Display Abnormal Homeostatic Responses to Challenges of Increased Dietary Fat and Cold Endocrinology, June 1, 2003; 144(6): 2580 - 2587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wang and C. M. Kotz Urocortin in the lateral septal area modulates feeding induced by orexin A in the lateral hypothalamus Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2002; 283(2): R358 - R367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. P. Bakshi, S. Smith-Roe, S. M. Newman, D. E. Grigoriadis, and N. H. Kalin Reduction of Stress-Induced Behavior by Antagonism of Corticotropin-Releasing Hormone 2 (CRH2) Receptors in Lateral Septum or CRH1 Receptors in Amygdala J. Neurosci., April 1, 2002; 22(7): 2926 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Li, J. Vaughan, P. E. Sawchenko, and W. W. Vale Urocortin III-Immunoreactive Projections in Rat Brain: Partial Overlap with Sites of Type 2 Corticotrophin-Releasing Factor Receptor Expression J. Neurosci., February 1, 2002; 22(3): 991 - 1001. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
